Overview

Assessment of Efficacy of Vardenafil in the Treatment of Subjects With Symptomatic Benign Prostatic Hyperplasia

Status:
Completed
Trial end date:
2006-06-01
Target enrollment:
Participant gender:
Summary
Assessment of efficacy of vardenafil in the treatment of subjects with symptomatic Benign Prostatic Hyperplasia.The purpose of this study is to find out whether vardenafil can improve the lower urinary tract symptoms of benign prostatic hyperplasia after 8 weeks of daily administration of 10 mg BID.
Phase:
Phase 2
Details
Lead Sponsor:
Bayer
Treatments:
Vardenafil Dihydrochloride